tissue-engineering
(6)
Adam Kinsey Built His Career in the Space Between the Lab and the Ledger
The Ventrix co-founder trained as an engineer, learned the grammar of patents and then spent more than a decade turning an academic biomaterial into a company built for the long haul.
Keith Murphy Keeps Asking Biology to Speak for Itself
After helping build the first commercial chapter of 3D bioprinting, the chemical engineer returned to the stubborn question underneath it all: can a small piece of human tissue make a better decision than a celebrated animal model?
Caralynn Nowinski Collens
Caralynn Nowinski Collens is a physician-turned-entrepreneur and the co-founder and CEO of Dimension Bio (formerly Dimension Inx), a Chicago biotechnology company building regenerative therapeutics that give the body a blueprint to heal itself. Its BioNidum platform fuses materials science, 3D-printing, and digital manufacturing to turn cells into implantable, tissue-like therapies. Before biotech, she spent eight years co-founding and running UI LABS, the innovation collaborative that launched MxD, the U.S. national hub for digital manufacturing. She trained as an M.D./MBA at the University of Illinois at Chicago and has been recognized on Crain's Forty Under Forty, Tech 50, and Notable Women in STEM lists.
Andrei Georgescu
Andrei Georgescu is the co-founder and CEO of Vivodyne, a biotech company that grows human tissues in the lab and runs drugs through them with robots and AI before any human ever swallows a pill. A University of Pennsylvania bioengineering PhD who once sent lab-grown tissue to space with NASA, he started Vivodyne in 2020 because roughly 19 of every 20 drugs that work in animals fail in people. His pitch is blunt: test human medicine on human tissue, not on mice. In May 2025 Vivodyne raised a $40 million Series A led by Khosla Ventures to scale a 23,000-square-foot fully robotic lab in South San Francisco.
Nicholas Geisse
Nicholas Geisse is the CEO of Curi Bio, a Seattle biotech building human-relevant tissue platforms that make lab-grown muscle and heart cells behave more like the real thing. A Cambridge-trained pharmacologist who learned to wire up tiny instruments in Kevin Kit Parker's cardiac engineering lab at Harvard, he spent years at Asylum Research selling and designing atomic force microscopes before joining Curi Bio as Chief Science Officer in 2017. He led development of the Mantarray 3D engineered-muscle-tissue platform and the company's NIH-backed R&D program, then stepped up to chief executive in 2023. His work has collected an Xconomy 'Big Idea' award, an SBA Tibbetts award, and an Edison Award.
Vincent Ling
Vincent Ling is the Chief Business Officer of Morphocell Technologies, a Laval-based regenerative medicine company building iPSC-derived engineered tissues to treat severe organ dysfunction, starting with liver disease. A biotech and pharma veteran of three decades, he spent 12 years at Takeda's Center for External Innovation, where he identified and backed the Kariko-Weissman mRNA platform out of the University of Pennsylvania - the science that became the first COVID mRNA vaccines and earned the 2023 Nobel Prize. He has held leadership roles at Genetics Institute, Adnexus Therapeutics, and Neurotech Pharmaceuticals, and advises the Gates Foundation and academic institutions.